Swish: FDA greenlights 'game-changing' COVID-19 saliva test used by the NBA McKesson signs up with Warp Speed to distribute COVID-19 shots in U.S. After hydroxychloroquine, Trump sets sights on another unproven COVID-19 treatment: report HHS allocates $1.4B to children's hospitals affected by COVID-19 Coming COVID-19 vaccination wave will generate $20B in sales next year: analyst New Jersey medical office sues Cigna over denied COVID-19 testing, treatment claims Chinese regulators pen requirements for COVID-19 vaccine approval—and they're stricter than the FDA's UCSF engineers develop llama-inspired 'AeroNabs' to strangle COVID-19 with an inhaler More than a third of disrupted cancer trials back on track: report Biopharma roundup: NIAID looks to develop new virus strain for challenge trials; FDA green lights spit test used in NBA 'bubble' Even in the coronavirus era, U.S. pharma and biotech employees say jobs secure: survey Featured Story | By Conor Hale The rapid, saliva-based coronavirus test used to screen NBA players within “the bubble” as they work through their current basketball season has now been authorized by the FDA for use across the country. read more |
| |
|---|
|
Top Stories By Kyle Blankenship The U.S. government has placed a series of multibillion-dollar bets on potential cororavirus vaccines. Actually getting hundreds of millions of doses to patients is another story, though—and now, in a deal reportedly worth up to $300 million, the government has tapped a major distributor to aid that effort. read more By Eric Sagonowsky Now that the intense hydroxychloroquine debate has lost steam, President Trump is reportedly eyeing another “miracle” therapy without evidence to back it up. The president and allies see oleandrin, an extract of the oleander plant, as a useful dietary supplement—or even an FDA-approved therapy—to treat or prevent COVID-19, Axios reports. read more By Robert King The Department of Health and Human Services is allocating $1.4 billion in targeted funds to certain children's hospitals hit hard by the COVID-19 pandemic. read more By Eric Sagonowsky With leading COVID-19 vaccines moving into late-stage testing and rollouts possible in late 2020 or early 2021, analysts are starting to make predictions about what the market will look like. In all, Bernstein analyst Ronny Gal predicts the market will be worth $20 billion next year. read more By Paige Minemyer A New Jersey medical office has filed suit against Cigna, alleging that the insurer failed to pay for diagnostic testing and treatment related to COVID-19, in violation of the CARES Act. read more By Angus Liu Weeks after the FDA rolled out its standards for approving COVID-19 vaccines, its Chinese counterpart has released its own guidance with some similar criteria, requiring a candidate to be at least 50% more effective than placebo. But unlike the U.S. agency, China's NMPA has specified the length of protection it wants to see. read more By Arlene Weintraub UCSF researchers engineered a three-part antibody chain to block COVID-19 that's inspired by the tiny nanobodies that llamas and other camelids make naturally to fight off pathogens. They believe the treatment could be delivered as an aerosol and used as a self-administered form of protection against the virus. read more By Ben Adams Oncology studies were some of the hardest hit in the first few months of the pandemic, but more than a third have now resumed. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner The NIAID is looking ahead to possible challenge trials, and plans to create a strain of the coronavirus for such tests. The FDA approved a spit test popularly used by the NBA. Vaccines will bring in $20 billion next year, one analyst figures. Biological E snagged a vaccine plant from Akorn as it scales up to make J&J's shot. And Philips is deploying ICU kits to hard-hit hospitals. read more By Beth Snyder Bulik Pandemic woes have workers fearing for their jobs across the U.S., but at least so far, the life sciences industry is largely immune. Pharma and biotech employees are confident in their employment and salary prospects, the search firm EPM Scientific found in a new survey—and the firm itself has seen no decline in demand for recruits across the field. read more |
